Publications

Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi I, Sato T, Shaheen M, Zhao L, Kelley H, Liu H, Kumar S, Bobilev D, Krieg AM, Wooldridge JE, Kirkwood JM. Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025. PMID: 40753466

Beresis R, Prathigudupu V, Cable C, Yu A, Adler M, Ramamoorthi R, Yeon SK, Gordan JD, Sharma S, DeGrado WF, Zaro B, Chen JY, Jo H. Exploration of a Class of Aryl Imidazolyl Ureas As Potent Acid Ceramidase Inhibitors for the Treatment of Fibrotic Diseases. ACS omega. 2025. PMID: 40821548

Chen HY, de Kouchkovsky I, Bok RA, Ohliger MA, Wang ZJ, Gebrezgiabhier D, Nickles T, Carvajal L, Gordon JW, Larson PEZ, Kurhanewicz J, Aggarwal R, Vigneron DB. Correction: Chen et al. Multivariate Framework of Metabolism in Advanced Prostate Cancer Using Whole Abdominal and Pelvic Hyperpolarized 13C MRI-A Correlative Study with Clinical Outcomes. Cancers 2025, 17, 2211. Cancers. 2025. PMID: 40805300

Hawes MR, Chakravarty D, Cheng J, Handley MA, Tsoh JY, Lin TK, Hiatt RA, Vijayaraghavan M. The Healthy Homes Study: Protocol for a cluster randomized trial of a place-based smoke-free home intervention in affordable housing. PloS one. 2025. PMID: 40729126

Chan SL, Sun HC, Xu Y, Zeng H, El-Serag HB, Lee JM, Schwartz ME, Finn RS, Seong J, Wang XW, Paradis V, Abou-Alfa GK, Rimassa L, Kao JH, Zhang BH, Llovet JM, Bruix J, Yip TC, Wong VW, Wong GL, Chan LL, Liu MQ, Gao Q, Shen F, Kelley RK, Cheng AL, Kurosaki M, Toyoda H, Chen WX, Murakami T, Liang P, Zucman-Rossi J, Minami Y, Miyayama S, Wang K, Man K, Hasegawa K, Li Q, Tsuchiya K, Xu L, Chew V, Chow P, Hoshida Y, Lujambio A, Ng IO, Sakamoto M, Park YN, Yau T, Kudo M, Fan J, Zhou J. The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment. Lancet (London, England). 2025. PMID: 40744051

Wesolowski R, Rugo HS, Specht JM, Han H, Kabos P, Vaishampayan U, Wander SA, Gogineni K, Spira A, Schott AF, Abu-Khalaf M, Mutka SC, Suzuki S, Sullivan B, Gorbatchevsky I, Layman RM. Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40711480

Milhem MM, Wise-Draper TM, Chandra S, Hanna GJ, Laux DE, Medina TM, Ansstas G, Daud A, Kelly CM, O'Day SJ, Perez CA, Wong MK, Friedlander PA, Kristedja TS, Burgess MA, Cowey CL, Hanks BA, Weight RM, Daniel WL, Feltner DE, Mix S, Sindelar L, Bexon AS, Bexon MF, Michel RE, Bhatia S. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. Journal for immunotherapy of cancer. 2025. PMID: 40713179

Park J, Kwon DY, Sue R, Bahl K, Wang A, Gamboa S, Linker AS, Aoun R, Abraham C. Increasing the Rates of Postpartum Measles, Rubella, and Varicella Vaccination in Nonimmune Mothers: An Electronic Medical Record-Based Quality Improvement Intervention. American journal of perinatology. 2025. PMID: 40633814

Mukhtar RA, Dimitroff K, Yau C, Chien AJ, Connolly EP, Howard-McNatt M, Rao R, Ladores V, Golshan M, Sauder CA, Ahmed K, Lancaster R, Fox J, Gutnik L, Lee MC, Tchou J, Prionas N, Arciero CA, Reyna C, Kuerer H, Switalla K, Taunk N, Tuttle TM, Moran MS, Postlewait LM, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Rugo HS, Shatsky R, Isaacs C, Esserman LJ, Van't Veer L, Boughey JC. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial. Annals of surgical oncology. 2025. PMID: 40705266

Riechelmann RP, Torrezan GT, Bergsland E, Raj N, Strosberg J, Moon F, Felismino TC, Knappskog S, Trevizani E, Cingarlini S, Sorbye H. Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study. Therapeutic advances in medical oncology. 2025. PMID: 40727887

Kaur M, Dimitroff K, Boughey JC, Esserman LJ, Yau C, Tchou J, Quirarte A, Lee MC, Howard-McNatt MM, Switalla K, Kuerer H, Sauder C, Postlewait LM, Arciero C, Rao R, Wallace A, Reyna C, Ahmed K, Gutnik L, Taunk N, Perlmutter J, DeMichele A, Yee D, Hylton NM, Symmans WF, Rugo HS, Shatsky RA, Isaacs C, Rudra S, Pohlmann P, Ewing C, Wong J, Alvarado M, Jaskowiak N, Prionas N, Golshan M, Piltin MA, Olopade OI, Mukhtar RA. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial. Annals of surgical oncology. 2025. PMID: 40699532

Hawes M, Alway J, Chakravarty D, Kushel M, Max W, Xia F, Neyazi N, Vijayaraghavan M. Cigarette smoke-free home adoption attempts among formerly homeless adults living in permanent supportive housing. Drug and alcohol dependence reports. 2025. PMID: 40762021

Zeng Q, Flemming L, Chen Y, Mazumder T, Hammerlindl H, Allen GM, Almeida R, Williams JZ, Hernández-López RA, Eyquem J, Ye CJ, Lim WA, Tang Q, Desai TA, Huang X. Programmable microparticles rewire CAR signaling to enable super-physiological expansion of human T cells in vitro. bioRxiv : the preprint server for biology. 2025. PMID: 40777491

Lynce F, Liu X, Li B, McRoy L, Chen C, Liu R, Rugo HS. Real-world effectiveness of palbociclib plus an aromatase inhibitor in HR+/HER2- MBC patients living in disadvantaged neighborhoods. NPJ breast cancer. 2025. PMID: 40691446

Corcoran CJ, Cuthbert BJ, Glanville DG, Terrado M, Valverde Mendez D, Bratton BP, Schemenauer DE, Tokars VL, Martin TG, Rasmussen LW, Madison MC, Maule AF, Shaevitz JW, Tseng BS, Whitelegge JP, Putonti C, Gaggar A, Beach JR, Kirk JA, Mondragón A, Kroken AR, Allen JP, Goulding CW, Ulijasz AT. A glyoxal-specific aldehyde signaling axis in Pseudomonas aeruginosa that influences quorum sensing and infection. Nature communications. 2025. PMID: 40681494

Roy S, Sun Y, Eastham JA, Gleave M, Wallis CJD, Beltran HA, Kishan AU, Jia AY, Zaorsky NG, Nagar H, Garcia JA, Small EJ, Nguyen P, Attard G, McKay RR, Sartor O, Berlin A, Rosenthal SA, Halabi S, Vince R, Ponsky L, Morgan SC, Hannan R, Raben A, Roach M, Michalski JM, Morris MJ, Sandler HM, Spratt DE. Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer. European urology oncology. 2025. PMID: 40683825

Vicini F, Shah C, Mittal K, Weinmann S, Leo M, Mann GB, Warnberg F, Rabinovitch R, Czerniecki B, Meattini I, Khan AJ, Jhawar S, Gerber N, Willey SC, Borgen P, AlHilli Z, Kruse M, Dabbs D, Shivers SC, Daily A, Whitworth P, Alvarado M, Mouabbi JA, Moran M, Rugo H, O'Shaughnessy JA, Bremer T. Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Rec International journal of radiation oncology, biology, physics. 2025. PMID: 40685017

Reuss JE, Kuruvilla S, Ismaila N, Azar IH, Feldman J, Furuya N, Wheatley-Price P, Roof L, Velazquez AI, Wang Y, Leighl NB. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2025.1. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40674661

Minichiello V, Ring M, Adler SR, Bora S, Chiasson AM, Garber TS, Dhruva A, Hu K, Kogan M, Kohatsu W, Dog TL, Mehta DH, Rindfleisch A, Schneiderhan J, Soriano S. Reimagining integrative medicine fellowship core competencies with a health equity lens. The American journal of medicine. 2025. PMID: 40681011

Brooks TR, Zabor EC, Bedelu Y, Yang X, Karimi YH, Nedved AN, Wang Y, Dave NK, Landsburg DJ, Baron K, Hu B, Trotier D, Pophali PA, Miller J, Grover NS, Reinert C, Major A, Schwarz T, Patel K, Salafian K, Ayers EC, Sundaram S, Brody JD, McKenna M, Tiger YKR, Sears-Smith M, Ghosh N, Peterson C, Khan C, Bliven SP, Narkhede M, Gibson A, Kline J, Munoz J, Garza Morales R, Ho C, Smith SD, Niu A, Hernandez-Ilizaliturri FJ, Chinyengetere F, Dave SS, Abdel-Razeq N, Alhaj Moustafa M, Caimi P, Hill BT. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025. PMID: 40663785